Preventive lung, breast, and prostate cancer screening at community resource spots
Official title: Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
Run by AdventHealth · NCT07231159 · Data updated 2026-11-12
This program tries community outreach at resource centers to help underserved adults get screening, follow-up diagnosis, and treatment for lung, breast, and prostate cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | AdventHealth Academic / other |
| Locations | 1 site (Orlando, Florida) |
| Status | Recruiting |
| Started | November 17, 2025 |
| Main results expected | August 30, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | November 17, 2025 |
| Trial ID | NCT07231159 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18+ seeking care at participating community resource spots or the emergency department who meet screening age/risk criteria (women 40–74 for breast, adults 50–80 with a 20+ pack-year smoking history for lung, men 55–69 for prostate) and have a positive screening result at a study site.
✕Probably not a fit
Patients who do not meet the screening criteria, refuse screening, or whose behavior is disruptive and prevents participation would not be eligible and are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program uses community resource spots and emergency departments to connect underserved adults with screening and to coordinate referrals for diagnostic follow-up. It applies the RE-AIM implementation framework to measure reach, effectiveness, adoption, implementation, and maintenance of the outreach and engagement activities. Eligible participants who meet age and risk criteria and receive a positive screening result are referred for definitive diagnosis and linked with engagement/navigation services. The work is led by AdventHealth in Orlando with collaboration from the Florida Department of Health.
Why it matters
Potential benefit: If successful, the program could increase early detection and timely follow-up care for underserved adults with screening-detected lung, breast, or prostate cancers.
How similar studies have gone: Similar community outreach and patient navigation programs have previously improved screening uptake and diagnostic follow-up, so this approach builds on established methods rather than being entirely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult aged 18 or older 2. Seeking care at a CRS or emergency department 3. Meets criteria for lung, breast, and/or prostate cancer screening, as outlined below: 1. Lung cancer: Adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years 2. Breast cancer: Women aged 40 to 74 years 3. Prostate cancer: Men aged 55 to 69 years 4. Receives a positive screening result for lung, breast, and/or prostate cancer at a study site Exclusion Criteria: 1. Displays behavior disruptive to other patients or staff 2. Refusal to accept screening for breast, lung, and/or prostate cancers
Where it's running
-
Adventhealth
Orlando, Florida, United States Recruiting
Study contacts
- Principal investigator: Mark Socinski, MD — AdventHealth
- Study coordinator: Patricia Robinson, PhD
- Email: patricia.robinson@adventhealth.com
- Phone: 407-303-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers
This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
-
HER2 FPBMC therapy for metastatic breast and prostate cancer
This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.